Forecast

The analysts' average price target is +10,30€ (+765,55%). The median is +10,30€ (+765,55%).

Buy	5
Hold	1
Sell	0

News Go to news feed

Exicure renews board and appoints two new directors

Exicure has accepted the resignation of Jung Kyu Ham, expanded the board from five to six directors, and appointed Jin Young Go and Eui Seok Han effective immediately as Class-III directors. The board confirms that Eui Seok Han meets NASDAQ requirements as an independent director and that a majority of the board remains independent. The board confirmed the audit committee and established a compensation committee; the company is reviewing strategic alternatives following a restructuring. The stock has fallen sharply year to date (−68.75%) and currently trades at around $2.20 with a market capitalization of about $15.3 million. » More on de.investing.com
Exicure: Sangjin Yeo resigns from board of directors and audit committee

Sangjin Yeo resigned his mandate on Exicure’s board of directors and its audit committee effective last Friday. The company said the resignation was not due to disagreements over business operations, policies or practices. No information was given on a replacement or changes to the committees. » More on de.investing.com
Restructuring at Exicure: CEO and CFO resign, board reshuffled

Exicure has accepted the resignations of CEO Andy Yoo and CFO Seung Ik Baik effective Feb. 9 and appointed three new directors—Jung Kyu Ham, Jung Soo Kim and Gyeung Seog Cheon; successors for CEO and CFO have not yet been named. The company, with a market capitalization of about USD 27.8 million, has seen its share price fall by more than 20% year-to-date. Baik will receive a severance payment of USD 150,000; the new directors will each receive USD 20,000 in annual compensation. In parallel, Exicure reports progress in Phase 2 clinical trials (Burixafor: ~90% achieving the primary endpoint) and the internal repayment of convertible notes totaling USD 3.1 million. » More on de.investing.com

Financials

In the last quarter, EXICURE INC had revenue of 0,00€ and net profit of −982,23k€

(EUR)	Jun 2026	YoY
Revenue	0,00	-
Gross profit	0,00	-
Net profit	−982,23k	55,83%
EBITDA	−947,18k	51,90%

Fundamentals

Metric	Value
Market capitalization	+7,60M€
Number of shares	6,37M
52-week high/low	+8,13€ - +0,90€
Dividends	No
Beta	3,66
P/E ratio	−1,06
PEG ratio	+0,01
P/B ratio	+9,07
P/S ratio	0,00

Company profile

Exicure, Inc. ist ein Biotechnologieunternehmen, das Therapien für neurologische Erkrankungen und Haarausfall auf der Grundlage seiner proprietären sphärischen Nukleinsäuretechnologie (SNA) entwickelt. Zu seinem führenden Programmkandidaten gehört SCN9A, das sich in präklinischen Studien zur Behandlung neuropathischer und chronischer Schmerzen befindet. Das Unternehmen hat eine Kooperations-, Options- und Lizenzvereinbarung mit AbbVie Inc. zur Entwicklung von SNA-basierten Behandlungen für Haarausfallerkrankungen und eine Kooperationsvereinbarung mit Ipsen S.A. zur Erforschung, Entwicklung und Vermarktung neuartiger sphärischer Nukleinsäuren für die Huntington-Krankheit und das Angelman-Syndrom. Exicure, Inc. wurde im Jahr 2011 gegründet und hat seinen Hauptsitz in Chicago, Illinois.